Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.74 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.74 |
| ▸ | HTR3A | P46098 | 1/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7280241 | 0.99 | PDE5A (1.00) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7287234 | 0.92 | PDE5A (0.85) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7287473 | 0.87 | PDE5A (1.00) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7435275 | 0.86 | PDE5A (0.78) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7278451 | 0.86 | PDE5A (0.78) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7278185 | 0.86 | PDE5A (0.78) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7431206 | 0.86 | PDE5A (0.78) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| Hydrochloric Acid SCHEMBL7287466 | 0.86 | PDE5A (1.00) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7280806 | 0.86 | PDE5A (1.00) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| Hydrochloric Acid SCHEMBL7286771 | 0.85 | PDE5A (0.78) | PDE5ATBXAS1PDE3BPDE3APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090041675-A1 | Organic compounds | TRIFILIEFF ALEXANDRE | 2009-02-12 | — | — | US | claimed |
| US-20070197560-A1 | cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction | NAEF RETO | 2007-08-23 | — | — | US | claimed |
| EP-1140044-B1 | cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION | NOVARTIS AG (CH) | 2006-03-15 | — | — | EP | claimed |
| US-20040214831-A1 | cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction | NAEF RETO | 2004-10-28 | — | — | US | claimed |
| US-20010055570-A1 | Cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs); using specified pyrazolopyrimidinone or aminoquinazoline derivatives | NAEF RETO (CH) | 2001-12-27 | — | — | US | claimed |
| EP-0579496-B1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO (JP) | 2001-11-14 | — | — | EP | claimed |
| US-6300335-B1 | UROGENITAL DISORDERS | PFIZER INC. | 2001-10-09 | — | — | US | claimed |
| EP-0579496-A1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-01-19 | — | — | EP | claimed |
| US-10994082-B2 | Inhaler counter | ASTRAZENECA AB (SE) | 2021-05-04 | — | — | US | disclosed |
| US-20190175849-A1 | INHALER COUNTER | BANG & OLUFSEN MEDICOM A/S (DK) | 2019-06-13 | — | — | US | disclosed |
| US-20180339119-A1 | INHALER | BANG & OLUFSEN MEDICOM A/S (DK) | 2018-11-29 | — | — | US | disclosed |
| EP-2755707-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-11-14 | — | — | EP | disclosed |
| EP-3345644-A1 | INHALER | Astrazeneca AB (SE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2755708-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-05-09 | — | — | EP | disclosed |
| WO-2000037061-A3 | cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION | NOVARTIS AG (CH) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000037061-A2 | cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION | NOVARTIS AG (CH) | 2000-06-29 | — | — | WO | disclosed |
| WO-1999059584-A1 | COMBINATION OF PHENTOLAMINE AND CYCLIC GMP PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | SCHERING CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| US-5436233-A | Nervous system disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0579496-A1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041675-A1 | Organic compounds | PDE12, PDE5A, RXFP4 | PDE5A 2/4885TBXAS1 529/4885PDE3B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.